Gamma Therapeutics is a Portland, Oregon biotechnology venture developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry based upon a natural clotting protein in blood called Gamma Prime  Fibrinogen. The Gamma Therapeutics product line includes its provisional-patented flagship product, GammaCoeur™, a cardiovascular disease risk diagnostic assay; GammaSeal™, a patent-pending, high strength post-surgical incision sealant, and; Gammarin™, a patented non-immunogenic blood anti-coagulant.

Click here to download the Gamma Therapeutics Fact Sheet.

Copyright © 2010, Gamma Therapeutics, Inc. All rights reserved.